 Zacks Investment Research upgraded shares of Health Catalyst NASDAQ:HCAT from a sell rating to a buy rating in a research note published on Wednesday morning, Zacks.com reports. The firm currently has 36.00 price objective on the stock. According to Zacks, Health Catalyst Inc. is a provider of data and analytics technology and services to healthcare ... 